- Home
- NRSN vs RAND Comparison
NRSN vs RAND Comparison
Compare NRSN & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- RAND
- Stock Information
- Founded
- NRSN 2017
- RAND 1969
- Country
- NRSN Israel
- RAND United States
- Employees
- NRSN N/A
- RAND N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- NRSN Health Care
- RAND Finance
- Exchange
- NRSN Nasdaq
- RAND Nasdaq
- Market Cap
- NRSN 50.1M
- RAND 54.4M
- IPO Year
- NRSN 2021
- RAND N/A
- Fundamental
- Price
- NRSN $1.06
- RAND $16.13
- Analyst Decision
- NRSN Buy
- RAND
- Analyst Count
- NRSN 2
- RAND 0
- Target Price
- NRSN $14.00
- RAND N/A
- AVG Volume (30 Days)
- NRSN 353.2K
- RAND 5.0K
- Earning Date
- NRSN 09-29-2025
- RAND 08-04-2025
- Dividend Yield
- NRSN N/A
- RAND 10.35%
- EPS Growth
- NRSN N/A
- RAND N/A
- EPS
- NRSN N/A
- RAND N/A
- Revenue
- NRSN N/A
- RAND $7,966,118.00
- Revenue This Year
- NRSN N/A
- RAND N/A
- Revenue Next Year
- NRSN N/A
- RAND N/A
- P/E Ratio
- NRSN N/A
- RAND N/A
- Revenue Growth
- NRSN N/A
- RAND 1.16
- 52 Week Low
- NRSN $0.68
- RAND $13.82
- 52 Week High
- NRSN $2.60
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- NRSN 33.59
- RAND 46.94
- Support Level
- NRSN $1.05
- RAND $15.17
- Resistance Level
- NRSN $1.17
- RAND $16.20
- Average True Range (ATR)
- NRSN 0.12
- RAND 0.94
- MACD
- NRSN 0.01
- RAND 0.06
- Stochastic Oscillator
- NRSN 10.00
- RAND 71.52
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.